logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Survival and the use and costs of hospital services for London AIDS patients treated with AZT.

    Article - En anglais

    The aim of this study was to evaluate the survival patterns and use and cost of hospital services of AIDS patients treated with azidothymidine (AZT) at St Mary's Hospital, London.

    A retrospective analysis of inpatient and outpatient case notes was performed, as was a survey of HIV-related care costs in 37 clinical departments.

    Of the 183 AIDS patients managed between 1 January 1987 and 30 September 1989,132 were treated with AZT and 51 without AZT.

    Mean age at time of AIDS diagnosis for these predominantly homosexual men was 37.5 years for those treated with AZT compared with 40.7 years for those not on AZT.

    Median survival time from date of AIDS diagnosis was significantly longer for patients treated with AZT compared with those not treater with AZT (23 vs 13.5 months, P=0.0004).

    The interval from diagnosis of HIV infection to date of AIDs diagnosis did not differ significantly between groups.

    Inpatient and outpatient use of services was greater for those receiving AZT than for those who did not.

    Costs reflected this increased use of services and the costs for those treated with AZT were £3061 per AIDS patient-year higher compared with AIDS patients not receiving AZT ; 36% of this cost was directly attributable to the cost of AZT itself. (...)

    Mots-clés Pascal : SIDA, Virose, Infection, Zidovudine, Antiviral, Chimiothérapie, Traitement, Survie, Pronostic, Analyse coût, Prescription, Economie santé, Angleterre, Grande Bretagne, Royaume Uni, Europe, Homme, Immunopathologie, Immunodéficit, Pyrimidine nucléoside

    Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Zidovudine, Antiviral, Chemotherapy, Treatment, Survival, Prognosis, Cost analysis, Prescription, Health economy, England, Great Britain, United Kingdom, Europe, Human, Immunopathology, Immune deficiency, Pyrimidine nucleoside

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0163612

    Code Inist : 002B06D01. Création : 21/05/1997.